Company intelligence / Profile preview
Angiochem Inc.
Montreal, Quebec, Canadaangiochem.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ANG1005 (peptide-paclitaxel conjugate) is in Phase III clinical trials for brain metastasis associated with breast cancer. Previous Phase II trials showed promising signs of anti-tumor activity in HER2+ and HER2- breast cancer patients with brain metastasis. ANG4043 (peptide-mAb conjugate targeting HER2) has shown efficacy in preclinical studies, achieving therapeutic brain concentrations and increasing median survival time by 78% in mouse models.
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Peptide drug conjugatessmall moleculesbiologics
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Geron (license and collaboration agreement in 2010)
Beyond the preview
Go deeper on Angiochem Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angiochem Inc..